T L Timme

1.0k total citations
23 papers, 899 citations indexed

About

T L Timme is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, T L Timme has authored 23 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in T L Timme's work include Prostate Cancer Treatment and Research (7 papers), Virus-based gene therapy research (6 papers) and CAR-T cell therapy research (4 papers). T L Timme is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Virus-based gene therapy research (6 papers) and CAR-T cell therapy research (4 papers). T L Timme collaborates with scholars based in United States, Spain and Japan. T L Timme's co-authors include Timothy C. Thompson, Guang Yang, Dov Kadmon, James A. Eastham, R E Moses, Yasutomo Nasu, Satoru Shimura, M E Hagensee, Thomas M. Wheeler and Chenghui Ren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Endocrinology and The Journal of Urology.

In The Last Decade

T L Timme

23 papers receiving 881 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T L Timme United States 16 530 241 239 226 166 23 899
B Endlich United States 12 642 1.2× 262 1.1× 131 0.5× 92 0.4× 122 0.7× 18 887
Joseph R. Testa United States 11 519 1.0× 390 1.6× 155 0.6× 191 0.8× 187 1.1× 14 981
Federica Riccardo Italy 22 424 0.8× 244 1.0× 168 0.7× 298 1.3× 217 1.3× 45 993
V P Sukhatme United States 12 722 1.4× 139 0.6× 156 0.7× 108 0.5× 132 0.8× 15 975
Patricia E. Murtha United States 13 586 1.1× 107 0.4× 342 1.4× 201 0.9× 50 0.3× 13 1.0k
Ronald W. Oxenhandler United States 15 774 1.5× 191 0.8× 224 0.9× 127 0.6× 170 1.0× 24 1.2k
Shin‐ichiro Numata Japan 11 559 1.1× 129 0.5× 161 0.7× 75 0.3× 171 1.0× 13 888
Roberta Ceruti Italy 15 356 0.7× 283 1.2× 65 0.3× 115 0.5× 171 1.0× 20 806
Annette Schmitz France 17 590 1.1× 160 0.7× 635 2.7× 72 0.3× 149 0.9× 40 1.3k
Andressa Ardiani United States 16 269 0.5× 447 1.9× 148 0.6× 236 1.0× 95 0.6× 19 819

Countries citing papers authored by T L Timme

Since Specialization
Citations

This map shows the geographic impact of T L Timme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T L Timme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T L Timme more than expected).

Fields of papers citing papers by T L Timme

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T L Timme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T L Timme. The network helps show where T L Timme may publish in the future.

Co-authorship network of co-authors of T L Timme

This figure shows the co-authorship network connecting the top 25 collaborators of T L Timme. A scholar is included among the top collaborators of T L Timme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T L Timme. T L Timme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Heming, Guang Yang, T L Timme, et al.. (2007). IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Therapy. 14(10). 819–827. 10 indexed citations
2.
Naruishi, Koji, T L Timme, Nobuyuki Kusaka, et al.. (2006). Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Therapy. 13(7). 658–663. 20 indexed citations
3.
Fujita, Tetsuo, T L Timme, Ken-ichi Tabata, et al.. (2006). Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Therapy. 14(3). 227–236. 17 indexed citations
4.
Saika, Takashi, Nobuyuki Kusaka, Vladimir Mouraviev, et al.. (2005). Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model. Cancer Gene Therapy. 13(1). 91–98. 4 indexed citations
5.
Shimura, Satoru, Yasutomo Nasu, Haruki Kaku, et al.. (2002). Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer and Prostatic Diseases. 5(4). 316–325. 15 indexed citations
6.
Nasu, Yasutomo, et al.. (2001). Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer and Prostatic Diseases. 4(1). 44–55. 30 indexed citations
7.
Timme, T L, et al.. (1999). Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. APOPTOSIS. 4(4). 233–237. 47 indexed citations
8.
Nasu, Yasutomo, Chris H. Bangma, Satoru Shimura, et al.. (1999). Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy. 6(3). 338–349. 142 indexed citations
9.
Ren, Chenghui, et al.. (1998). Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer.. PubMed. 58(6). 1285–90. 76 indexed citations
10.
Stapleton, Alan M. F., Russel H. Williams, T L Timme, et al.. (1996). Human Cytomegalovirus is not Implicated in Benign Prostatic Hyperplasia: A Study Using Immunohistochemistry and the Polymerase Chain Reaction. The Journal of Urology. 156(2). 542–545. 1 indexed citations
11.
Thompson, Timothy C., et al.. (1996). Molecular biology of prostate cancer progression. International Journal of Radiation Oncology*Biology*Physics. 36(1). 114–114. 10 indexed citations
12.
Greene, Damian, Suzanne R. Taylor, Masahiro Aihara, et al.. (1995). DNA ploidy and clonal selection in ras + myc – Induced mouse prostate cancer. International Journal of Cancer. 60(3). 395–399. 1 indexed citations
13.
Timme, T L, et al.. (1995). Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World Journal of Urology. 13(6). 324–8. 15 indexed citations
14.
Thompson, Timothy C., T L Timme, James A. Eastham, et al.. (1995). Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.. PubMed. 10(5). 869–79. 96 indexed citations
15.
Eastham, James A., Alan M. F. Stapleton, Angelo E. Gousse, et al.. (1995). Association of p53 mutations with metastatic prostate cancer.. PubMed. 1(10). 1111–8. 90 indexed citations
16.
Timme, T L, L D Truong, V. Merz, et al.. (1994). Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis.. Endocrinology. 134(3). 1039–1045. 73 indexed citations
17.
Timme, T L. (1994). Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 134(3). 1039–1045. 22 indexed citations
18.
Wood, Chris M., T L Timme, Myra M. Hurt, et al.. (1987). Transformation of DNA repair-deficient human diploid fibroblasts with a simian virus 40 plasmid. Experimental Cell Research. 169(2). 543–553. 23 indexed citations
19.
Hagensee, M E, et al.. (1987). DNA polymerase III of Escherichia coli is required for UV and ethyl methanesulfonate mutagenesis.. Proceedings of the National Academy of Sciences. 84(12). 4195–4199. 65 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Endlich Breakdown of academic impact, for papers by Joseph R. Testa Breakdown of academic impact, for papers by Federica Riccardo Breakdown of academic impact, for papers by V P Sukhatme Breakdown of academic impact, for papers by Patricia E. Murtha Breakdown of academic impact, for papers by Ronald W. Oxenhandler Breakdown of academic impact, for papers by Shin‐ichiro Numata Breakdown of academic impact, for papers by Roberta Ceruti Breakdown of academic impact, for papers by Annette Schmitz Breakdown of academic impact, for papers by Andressa Ardiani
Rankless by CCL
2026